Industry Trend Analysis - CRISPR Potential Broadens As Research Accelerates - OCT 2017
BMI View: CRISPR technology will be embraced by big pharma , and Merck KGaA is amongst the first to bring the tec hnology in-house. Patent fights will ensue, unlikely producing a clear winner, resulting in cross-licensing deals . The breadth of potential targets with CRISPR, as highlighted by the significant preclinical results, will continue to attract attention , with rare diseases and cancer being the first targets that will make it through the clinic.
The European Patent Office (EPO) has issued a 'Notice of Intention to Grant' for Merck KGaA's patent application covering the company's CRISPR technology used in a genomic integration method for eukaryotic cells. The patent will provide Merck's CRISPR genomic integration technology with broad protection, further strengthening the company's patent portfolio. A related patent was approved in Australia in June 2017.
Merck Has Strong Heritage In Gene Editing